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Introduction 
 
Crohn’s disease (CD) is now diagnosed with increasing frequency at many centres in 
India. Intestinal tuberculosis (ITB) frequently encountered in our country is difficult to 
distinguish from CD as both diseases have similar radiological, endoscopic and histologic 
features.  Differentiation of CD from ITB is important both for planning treatment and 
assessing prognosis. 
 
 
Studies from the west have shown that there is a high prevalence of ASCA in Crohn’s 
disease. They have used this to differentiate Crohn’s disease from ulcerative colitis in 
patients with indeterminate inflammatory bowel disease. If the prevalence of ASCA is 
low in intestinal tuberculosis, it is possible that ASCA can be used as serological marker 
to help differentiate Crohn’s disease from intestinal tuberculosis. 
 
 
Anti Saccharomyces cerevisiae Antibodies (ASCA) are directed against cell wall oligo 
mannosidic epitopes of S.cerevisiae. The test is commercially available and is an ELISA 
based test which can be done in most laboratories.  
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Therefore the aim of the present study was to assess prevalence of ASCA in CD and ITB 
and evaluate the role of this serological marker in differentiating these 2 diseases. 
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AIMS 
 
• To  prospectively study  the prevalence of ASCA among patients with Crohn’s 
disease and intestinal tuberculosis and assess  the ability of  ASCA to differentiate 
Crohn’s disease from Intestinal tuberculosis 
 
• To assess the ability of clinical presentation,  radiology, endoscopy and 
histopathology to differentiate Crohn’s disease from intestinal tuberculosis 
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Review of Literature 
 
 
 
 
 9
 
Crohn's disease(CD) and intestinal TB (ITB)   are both chronic granulomatous conditions 
which affect the gastrointestinal tract in a similar manner and share clinical, enodscopic, 
radiological and histological features. Thus, often   it may be difficult to differentiate 
between the two. Establishment of correct diagnosis is essential because the treatment 
and prognosis of the two diseases are entirely different.  
Once considered rare in the developing world the epidemiology of IBD is changing and 
the incidence of both CD and ulcerative colitis (UC) is increasing in the Asian Pacific 
region, India, Eastern Europe and South Africa.1-4, 5  
 
 
Pathogenesis and genetics: 
Mycobacterium tuberculosis is the causative organism in ITB whereas the etiology of CD 
is multi-factorial and includes genetic, immunological, environmental and microbial 
factors.  Both trigger potent adaptive TH1 cytokine responses which result in granuloma 
formation and are characterized by robust production of interferon-gamma (IFN-γ), IL-12 
and IL-23. 
Current evidence suggests that CD may result from abnormal immune response to 
commensal gut bacteria in genetically predisposed patients 6 .  Gut Inflammation is kept 
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in check through an active process of immune tolerance. Two specific populations of T 
cells, T regulatory 1 and T helper 3 (Th3) cells, appear to have similar roles in 
maintaining mucosal tolerance in the intestine 7.    Failure of immune tolerance and over 
responsiveness of gut immune system to commensal microbes may lead to CD 8 .  The 
immune response is   skewed toward cell-mediated immunity. Th1 responses support 
cell-mediated immunity and a delayed hypersensitivity-type response 9. Th1 response 
leads to elaboration of a variety of injurious and proinflammatory substances 
(prostaglandins, reactive oxygen metabolites, nitric oxide, leukotrienes, and proteases) 
that are the ultimate cause of tissue destruction and granuloma formation. When the 
mucosal immune system in patients predisposed to the development of Crohn's disease is 
first exposed to an initiating antigenic stimulus, a dysregulated and overly aggressive 
cytokine-mediated T-cell response is mounted. Cytokines involved in innate immune 
responses, such as tumor necrosis factor (TNF- ), interleukin-1, interleukin-6, and 
possibly interleukins 12 and 18, may play a key role in this phase. The antigens that 
perpetuate the inflammatory response are taken up by macrophages. Degradation of 
antigen within proteosomes in macrophages results in presentation of an epitope in the 
context of the class II major histocompatibility complex (MHC). Interaction between 
MHC class II and the T cell receptor (CD3) results in antigen-specific interaction 
between the macrophage and the CD4+ T cell. This event is necessary to activate the T 
cell. Once CD4+ T cells are activated, effector cytokines involved in the adaptive 
immune response, including TNF-  and interferon- , as well as interleukins 4 and 13, 
mediate the effector phase of the intestinal inflammatory response. Novel cytokines such 
as TL1A and interleukins 23, 27, and 31 may also contribute to the effector phase10. 
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Expression of adhesion molecules is critical to amplify the immune response, because the 
resident populations of granulocytes and mononuclear cells alone do not account for the 
vigorous inflammatory reaction characterizing IBD. Adhesion molecules on the 
leukocyte surface and their ligands on the endothelium of venules in the lamina propria 
interact in a coordinated multistep process that permits trafficking of inflammatory cells 
into the mucosa. 
The sustained nature of the immune response in CD may have various causes. Poor 
intestinal barrier function may permit continued exposure of lamina propria lymphocytes 
to antigenic stimuli from the lumen. Poor barrier function also may be a factor in the 
onset of Crohn's disease, because such patients have increased intestinal permeability 
preceding clinical relapse of disease11.Alternatively, a sustained exaggerated 
inflammatory reaction may result from an ineffective immune response—resulting from a 
variety of defects—to an ever-present stimulus, as occurs in a number of conditions in 
humans in which there is a known immunologic defect.. Finally, the sustained nature of 
the inflammation may result from a programmed over-responsiveness to a persistent 
stimulus. Consistent with this theory is the finding that the mucosal T cells in patients 
with Crohn's disease have defective apoptosis12. This finding could account for the 
sustained nature of inflammation in IBD, because programmed cell death of lymphocytes 
is a normal mechanism for dampening immune response.  
 
    Mycobacterium tuberculosis is the pathogen responsible for most cases of intestinal 
tuberculosis, but rarely it may be caused by  M. bovis, an organism found in dairy 
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products,.  The organism penetrates the mucosa and stimulates Th1 type of immune 
response which leads to tissue destruction and granuloma formation in similar fashion as 
in Crohn’s disease. This leads to endoscopic and histologic similarities between the two 
disorders.   
 
CD is a complex genetic disorder. The relative risk among first-degree relatives is 14 to 
15 times higher than that of the general population which supports genetic   
predisposition 13. The concordance rate among monozygotic twins is as high as 67% for 
Crohn's   disease 14.    
  The presence of a locus on chromosome 16 (the so-called IBD1 locus) had been 
confirmed repeatedly to be linked to Crohn's disease, indicating the presence of a Crohn's 
disease gene in this region 15.  Two independent groups have identified the IBD1 locus as 
theNOD2 gene 16,  17.  NOD2 mediates the innate immune response to microbial 
pathogens, leading to activation of NF-κB. Persons with allelic variants on both 
chromosomes have a 40-fold relative risk of Crohn's disease compared to those without 
variantNOD2 genes17 . A locus on chromosome 12 (IBD2) has been observed less 
consistently, in both Crohn's disease. Other loci suggested having linkage to IBD include 
regions on chromosomes 1p, 1q, 3p, 3q, 6p, and 7.  
In contrast to CD the contribution of genetic mutations in intestinal TB has not been 
explored.  
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Pathology – ITB: 
Any part of GI tract can be involved but in three-fourth of cases ileocecal region is 
involved. Both sides of the ileocecal valve are usually involved, leading to incompetence 
of the valve, a finding that distinguishes tuberculosis from Crohn's disease. The other 
locations of involvement, in order of frequency, are the ascending colon, jejunum, sigmoi 
colon, rectum, duodenum, stomach and esophagus. 
Three broad categories of gross appearances have been recognized 18, 19   
 (1)Ulcerative lesions are seen in 60% of patients.  
(2) Hypertrophic lesions occur in 10% of patients. The condition consists of scarring, 
fibrosis, and heaped-up mass lesions that mimic carcinoma.  
(3) Ulcerohypertrophic lesions are seen in 30% of patients 
The bowel wall appears thickened, and there is an inflammatory mass surrounding the 
ileocecal region. Strictures and even fistula may be seen. The serosal surface is covered 
with multiple tubercles. The mesenteric lymph nodes frequently are enlarged and 
thickened. The mucosa is hyperemic, cobblestoned, edematous, and, in some cases, 
ulcerated. In contrast to Crohn's disease, the superficial ulcers tend to be circumferential, 
with the long axis perpendicular to the lumen. When these ulcers heal, the associated 
fibrosis causes stricture and stenosis of the lumen. 
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Histology reveals granuloma and caseation is not commonly seen in intestinal wall where 
as they found with regularity in regional lymph nodes. The muscularis usually is spared. 
Acid-fast bacilli may be seen in tissue sections and sometimes organism may be 
recovered in culture of the involved tissues. 
 
Pathology – CD: 
Most common location of disease is in the ileocecal region which is seen in upto half the 
cases. One third of patients have disease confined only to ileum and 25% with disease 
restricted to the colon 20. 
Linear or serpiginous ulcers may form when multiple ulcers fuse in a longitudinal 
direction. With transverse coalescence of ulcers, the classic cobblestoned appearance may 
arise, representing a network of ulcers surrounding relatively normal mucosa and 
prominent submucosal edema.  
Large ulcers, sinus tracts, and strictures are late features of Crohn's disease. As a result of 
the chronicity of the inflammatory process, free perforation is much less common than 
walled-off or contained intra-abdominal abscesses or fistulas to bowel, skin, bladder, or 
vagina. Fibrosis is another transmural aspect of the disease. Creeping mesenteric fat on 
serosa of bowel is highly suggestive of CD.21 
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The earliest lesion characteristic of Crohn's disease is the aphthous ulcer. The presence of 
granulomas is not unique in CD and is not seen in every case. Prevalence of granulomas 
in Crohn's disease have varied greatly, ranging from 15% in endoscopic series 22 to as 
high as 70% in surgical series 23. The granulomas are usually sparse, scattered, and not 
well formed. In contrast to the granulomas of tuberculosis, little or no central necrosis is 
present, and acid-fast stains and mycobacterial cultures are negative. Focal intestinal 
inflammation is the hallmark pathologic finding in Crohn's disease. -  focal crypt 
inflammation, focal areas of marked chronic inflammation, the presence of aphthae and 
ulcers on a background of little or no chronic inflammation, and the interspersing of 
segments of involved bowel with segments of uninvolved bowel. Transmural 
involvement is observed less commonly than disease of the mucosa and submucosa, but 
to the extent that transmural disease is noted, it is highly consistent with a diagnosis of 
Crohn's disease. The presence of lymphoid aggregates in both the submucosa and 
external to the muscularis propria are an accurate sign of Crohn's disease even when 
granulomas are not seen. 
 
Clinical Features: 
ITB: The clinical features are non specific. Abdominal pain is the predominant symptom 
seen in upto 90% of cases. Other symptoms are weight loss, fever, diarrhea or 
constipation, and blood in the stool 24.   Right iliac fossa mass may be present in some 
cases.  Malabsorption can occur when obstruction leads to proximal bacterial overgrowth. 
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Anemia, hypoalbuminemia and raised ESR may be the non specific laboratory 
abnormalities.  
CD: Clinical presentation depends on disease location with small bowel disease usually 
presenting as intestinal obstruction  25. Colonic disease typically presents as diarrhea 
which is sometimes blood mixed. Abdominal pain is a more frequent and persistent 
complaint. Pain may be intermittent and colicky in nature or sustained and severe. 
Constitutional symptoms, particularly weight loss and fever, or growth retardation in 
children may also be prominent 
Perianal skin lesions include maceration, superficial ulcers, and abscesses. Anal canal 
lesions include fissures, ulcers, and stenosis. The anal fissures of Crohn's disease tend to 
be placed more eccentrically than idiopathic fissures, which tend to occur along the 
midline Deeper abscesses may arise secondary to fistulas, especially when the internal os 
is located high in the rectum. 
Perianal fistulas are common, estimated to occur in 15% to 35% of patients. 
Fistulas from one segment of the gastrointestinal tract to another also occur frequently. 
Enteroenteric, enterocolonic, and colocolonic fistulas are often asymptomatic. Fistula to 
the vagina may occur with penetration from a severely inflamed rectal vault anteriorly or 
from the small bowel. Enterovaginal fistulas tend to occur among women who have had a 
hysterectomy, permitting direct extension to the adjacent vaginal cuff. Patients present 
with foul, persistent vaginal discharge and occasionally with passage of flatus or frank 
stool per vagina. Enterovesicular or colovesicular fistulas may present as recurrent 
polymicrobial urinary tract infection or as frank pneumaturia and fecaluria. These fistulas 
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are notoriously difficult to heal by nonsurgical means. Enterocutaneous fistulas to the 
anterior abdomen, often occurring after surgery, may be especially troublesome.  
Stricture is another characteristic complication of Crohn's disease. Symptoms may 
include colicky postprandial abdominal pain and bloating, punctuated by more severe 
episodes, and often culminating in complete obstruction. 
 
Diagnosis – ITB 
Histopathology may establish the definitive diagnosis of ITB if AFB can be seen in tissue 
section or necrotizing granuloma is seen. AFB recovered from tissue culture can also 
confirm the diagnosis. Colonoscopic findings, are nonspecific, consist of superficial areas 
of ulceration and a nodular friable mucosa,  mass lesion, stricturing26 . 
Radiographic examination of the bowel reveals a thickened mucosa with distortion of the 
mucosal folds, ulcerations, varying degrees of thickening and stenosis of the bowel, and 
pseudopolyp formation 27  28 .  Computed tomography may show preferential thickening 
of the ileocecal valve and medial wall of the cecum, extension to the terminal ileum, and 
massive lymphadenopathy with central necrosis.  The cecum is contracted with disease 
on both sides of the valve, and the valve itself is often distorted and incompetent. 
Tuberculosis tends to involve short segments of the intestine with stenosis and fistula 
formation. In the hypertrophic form a mass can be seen that resembles a cecal carcinoma. 
Calcified mesenteric lymph nodes and an abnormal chest x-ray are other signs that aid in 
the diagnosis of intestinal tuberculosis. 
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Diagnosis – CD 
The diagnosis is established through a total assessment of the clinical presentation with 
confirmatory evidence from radiographic, endoscopic, and in most cases, pathologic 
findings. Anemia, hypoalbuminamia, an elevated C-reactive protein or erythrocyte 
sedimentation rate, although not specific for IBD, may prompt further investigation.  
A small bowel follow-through study is the primary modality to evaluate for  small bowel 
disease - Early findings include aphthous ulcers, a coarse villous pattern of the mucosa, 
and thickened folds. Submucosal edema may be evident as thickening or flattening of the 
valvulae conniventes, whereas transmural edema manifests as widening of the separation 
between loops of bowel. Ulcers most often occur on the mesenteric border with 
consequent pseudosacculation of the antimesenteric border because of shortening of the 
mesenteric portion29  Later findings include a cobblestone appearance resulting from 
edema in relatively spared islands of mucosa that are separated by longitudinal and 
transverse knife-like clefts of ulceration29.  Still later, one may discern fistulas, sinus 
tracts, and fixed strictures.  
Computed tomography (CT) - mesenteric lymphadenopathy and transmural thickening of 
the bowel are usually seen. Fibrofatty proliferation of the mesentery, intra-abdominal and 
retroperitoneal abscess is other features. 
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Magnetic resonance imaging may provide visualization of complex perianal fistulas 
superior to pelvic CT 30. 
Endoscopy - aphthous ulcers, mucosal edema, cobblestoning and discontinuous 
segmental nature of the disease may be seen 31. 
Histopathology shows granuloma in most cases - they are usually sparse, scattered, not 
well formed with little or no central necrosis, and acid-fast stains and mycobacterial 
cultures are negative. Other features include   focal crypt inflammation, focal areas of 
marked chronic inflammation, the presence of aphthae and ulcers on a background of 
little or no chronic inflammation, and the interspersing of segments of involved bowel 
with segments of uninvolved bowel. Transmural involvement and presence of lymphoid 
aggregates in both the submucosa and external to the muscularis propria are other 
suggestive features on biopsy. 
 
Differentiating Crohn's Disease from ITB 
 
Distinguishing Crohn's disease from intestinal tuberculosis in endemic areas is 
challenging as both conditions have overlapping clinical, radiological, endoscopic and 
histological characteristics.  
In the developed world IBD diagnosis is less challenging due to low prevalence of 
chronic enteric infections. In contrast, IBD in the developing world is overshadowed by 
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enteric infections as well as resource constraints in utilizing technology, making the 
diagnosis of IBD difficult and presumptive diagnosis of infection common. 
There exists a multifaceted relationship between Crohn's disease (CD) and intestinal 
tuberculosis (ITB). They share common pathogenic and clinical characteristics and were 
thought to be one and the same disease till early twentieth century. 
Despite their morphological and immunopathogenic similarities, the natural history of 
these two conditions is divergent. ITB is associated with significant morbidity and 
mortality  but can be cured with a 6-month course of anti-tuberculous chemotherapy 32  33. 
By contrast, CD is a chronic condition that tends to progress with time and may require 
lifelong therapy to maintain disease remission in the majority of patients. In areas of 
high-TB prevalence, empiric treatment for TB with careful clinical review is often 
resorted to when diagnostic uncertainty exists. This approach is problematic as it may 
delay treatment for CD or make it difficult to confirm or refute a diagnosis of ITB at a 
later stage. Furthermore, severe adverse drug reactions to anti-tuberculous chemotherapy 
can complicate management with empiric therapy. Conversely treatment for CD may be 
disastrous if a diagnosis of intestinal TB is missed. 
Clinical Features: Both conditions are characterized by anorexia, loss of weight, 
abdominal pain, altered bowel habits, rectal bleeding or the presence of an abdominal 
mass. More acute presentations with intestinal perforation or obstruction, or intra-
abdominal abscess can also occur. One study from our institute showed that presence of 
significant loss of weight in an Indian patient with clinically suspected enteropathic 
arthropathy is an independent predictor of CD34.  
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The site of involvement is also similar with a predilection for the ileo-caecal region but 
both can involve the gastrointestinal tract from the mouth to anus. Fever is seen in both 
CD and ITB.  TB involvement of the lower limb joints, skin, eye and liver may mimic 
extra-intestinal CD. Immunologically mediated reactive polyarthritis (Poncet's disease), 
erythema nodosum, erythema induratum and uveitis can also be interpreted as 
manifestations of Crohn's 35 36 37. An association between inflammation and a 
hypercoagulable state is common to both Crohn's and tuberculosis. Patients with IBD are 
at a 3.6-fold increased risk of thromboembolic disease. Similarly, patients with active TB 
are at risk of deep vein thrombosis  38, 39 ,40 . 
Fistulization is one of the clinical hallmarks of CD. However, entero-enteric, entero-
cutaneous and peri-anal fistulas are all well described in intestinal TB41 42 43. In a South 
African series, 17% of peri-anal fistulas referred to a surgical department were 
tuberculous in origin 44  In a series from Taiwan, 8% of ITB patients presented with 
anorectal disease45. 
Routine laboratory tests and tuberculin skin testing: The use of tuberculin skin testing 
(TST) as a diagnostic tool in patients with ileo-colonic inflammation has limitations. 
Cross reactivity with BCG, a high prevalence of environmental mycobacteria and 
widespread latent M. tuberculosis infection makes interpretation of a positive TST 
difficult. Both Crohn's disease and ITB are associated with anaemia, leukocytosis, 
thrombocytosis, a low serum albumin and raised inflammatory markers. Routine blood 
tests play no role in the differentiation of CD from ITB.  
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Endoscopy: Colonoscopy with intubation of the terminal ileum combined with 
endoscopic mucosal biopsy is required in the evaluation of any patient with suspected CD 
or intestinal TB.  
The majority of ITB cases will involve the ileo-caecum with varying degrees of 
contiguous colon and small bowel involvement. In approximately 20% of cases, 
segmental colonic involvement occurs in the absence of ileo-caecal involvement and 
lesions in greater than two colonic sites, so-called skip lesions, may occur in up to 44% of 
patients46, 47, 26,  48.  Isolated small intestinal or upper gastrointestinal tract disease is also 
well described49, 41.  
The type of lesion rather than the distribution has become important in differentiating CD 
from ITB. Lee and colleagues in the first systematic prospective analysis evaluated 
endoscopic findings in 44 patients with ITB and 44 patients with CD. A scoring system 
comprising four endoscopic features of CD (anorectal lesions, longitudinal ulcers, 
apthous ulcers, cobblestone appearance) vs. four endoscopic features of ITB (transverse 
ulcers, pseudopolyps, involvement of fewer than four segments and a patulous ileo-caecal 
valve) was used. With this method, a positive predictive value for CD of 94.9% and 
88.9% for ITB was achieved50.  Table 1 shows comparison of endoscopic findings 
between CD and ITB patients. 
Table 1. Endoscopic Features of ITB and Crohn's Disease 
Intestinal TB Crohn's disease 
Ulcers have circumferential orientation Longitudinal orientation 
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Surrounding mucosa inflamed/nodular Surrounding mucosa normal 
Apthous ulcers uncommon Apthous ulcers common 
Hyperaemic nodules-isolated or in clusters Cobblestoning 
Pseudopolyps Multiple skip lesions 
Hypertrophic mucosa Anorectal lesions 
Strictures Strictures 
Destruction of ICV and/or caecum Preservation of ICV 
 
 
Histopathology: In areas endemic for M. tuberculosis, the differential diagnosis of CD 
and ITB poses a major challenge to pathologists as both conditions are characterized by 
granulomatous inflammation with overlapping histologic features. Most pathologists will 
be faced with this differential diagnosis in the context of endoscopic mucosal biopsies 
where the small sample size and superficial nature of the specimen further complicates 
the differential diagnosis. In ITB, the classical and pathognomonic features of caseating 
granulomatous inflammation and acid fast bacilli are present in <30% of cases. 26, 51, 52,53, 
54, 55, 56. 
A positive TB culture has a poor yield of <20% and the diagnosis is often delayed by 
several weeks. This has prompted the search for additional features that may assist in 
differentiating ITB from CD. Retrospective studies from Southern India and South Africa 
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have identified a number of features that appear helpful in distinguishing CD from ITB in 
colonoscopic biopsies 53-55. 
Apart from caseous necrosis and acid fast bacilli , features encountered exclusively, or far 
more frequently, in ITB include confluent granulomas, multiple granulomas in a given 
biopsy site, large granuloma size , bands of epithelioid histiocytes lining ulcers, 
submucosal granulomas and disproportionate submucosal inflammation, i.e. submucosal 
inflammation that significantly exceeds mucosal inflammation53-55 . 
Features seen far more frequently in CD include single granulomas and architectural 
distortion distant from granulomatous inflammation54. Prospective studies evaluating the 
clinical applicability of the above mentioned features in the differential diagnosis of ITB 
and CD are awaited with interest. The importance of taking multiple biopsies in cases of 
suspected ITB has been emphasized and significantly increases the diagnostic yield54. 
Biopsies should be taken from all segments of the bowel including both endoscopically 
normal and abnormal areas54. In particular, ulcerated areas should be thoroughly sampled 
(including multiple biopsies from both the base and the edge of the ulcer) as the 
diagnostic yield in ITB is highest in these lesions 57. Table 2 shows the comparison of 
histological findings in patients with CD vs. ITB. 
Table 2. Prevalence of Selected Histological Parameters in Patients with Intestinal 
Tuberculosis (ITB) and Crohn's Disease (CD): A Comparison of Three Similar 
Studies (values are in %)    
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Pulimood et al. 
(1999) Southern 
India55 
Pulimood et al. 
(2005) Southern 
India 54 
Kirsch et al. (2006), Cape 
Town, South Africa 53 
 
ITB (n = 
20) 
CD (n = 
20) 
ITB (n = 
33) 
CD (n = 
31) 
ITB (n 
= 18) CD (n = 25) 
Caseous necrosis 40 0 36 0 22 0 
Confluent granulomas 60 0 42 3 50 0 
≥5 granulomas/biopsy site 40 0 45 0 44 24 
≥10 granulomas/biopsy site -- -- -- -- 33 0 
Diameter > 200 µm Diameter > 400 µm Area > 0.05 mm2 Large granulomas 
90 5 51 0 67 8 
Submucosal granulomas 45 5 39 6 44 12 
Ulcers lined by bands of epithelioid 
histiocytes 
45 5 61 0 61 8 
Disproportionate submucosal 
inflammation 
65 5 -- -- 67 10 
Architectural distortion distant to 
granulomatous inflammation 
-- -- 0 62 -- -- 
. 
 
 
PCR: Several studies suggest a role for PCR for mycobacterial DNA in the differential 
diagnosis of ITB and CD,26 51, 52, 58, 59, 60.  Four retrospective studies on formalin-fixed, 
 26
paraffin embedded colonoscopic biopsy specimens reported positive results in 22% 
(13/60),51  45% (18/40) , 26  64% (25/39),52  75% (27/36)60 of ITB patients. Three of these 
also included biopsies from CD patients which were PCR was positive in 0% (0/30),52 
0% (0/26)60 and 5% (1/20)51 of cases. It is interesting to note that three studies reported 
the PCR detection rate to be no higher in biopsies with granulomas than in those without, 
,26, 51, 52 suggesting that PCR may have utility in histologically non-diagnostic cases. A 
recent prospective study evaluating the role of PCR for M. tuberculosis DNA in faecal 
samples reported positive PCR in close to 90% patients (16/18) with ITB compared with 
0/30 controls (predominantly patients with irritable bowel syndrome).59 Thus, the few 
published series to date suggest promise for PCR in the differential diagnosis of ITB and 
CD. Larger prospective studies from endemic areas are keenly awaited. 
 
Radiology: Barium studies allow visualization of the mucosal surface and luminal 
diameter and are valuable in demonstrating the inflammatory and cicatrising lesions 
found in both CD and ITB. Earlier work focussed on the pattern of ileo-caecal 
involvement as a means of diagnosing ITB. Examples of these include the Fleischner sign 
(a thickened patulous ICV combined with a narrowed terminal ileum) and Stierlin's sign 
(a rapid emptying of contrast through a gaping ileo-ceacal valve into a shrunken or 
'amputated' caecum)42,60 . A long segment of small intestinal involvement, with skip 
lesions and preservation of the IC valve and caecum were considered typical of CD. 
However, these radiological signs are non-specific for either ITB or CD and a variety of 
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other lesions such as ulcers, strictures, fistulas, fold thickening, mucosal nodules and 
bowel loop separation have been described in both conditions43,61 . 
 
 With contrast enhanced CT scanning and MRI-ITB findings in this region include 
asymmetric caecal wall thickening, an inflammatory mass centred around the caecum and 
enveloping the terminal ileum and small homogenous pericaecal lymph nodes 62,27. 
Features of CD include symmetrical bowel wall thickening, fibrofatty proliferation of the 
mesentry known as 'creeping fat', regional mesenteric nodes measuring 3-8 mm and 
enlarged mesenteric vascular bundles in the involved mesentry known as the comb sign 
63,64 .Extra-intestinal features of CD such as fatty liver, gallstones, primary sclerosing 
cholangitis and sacro-ileitis may also be seen on CT scan and MRI 63, 65.  
 
 
Functional MRI with improved luminal contrast techniques and CT enteroclysis allow 
better fistula definition and distinction between bowel wall fibrosis and inflammation65, 
66; however, the diagnostic capabilities of these new imaging modalities in environments 
with high rates for TB is unknown. At present conventional radiology in the majority of 
cases is not diagnostic. 
Laparoscopy: No systematic laparoscopic study comparing ITB to CD has been 
conducted. Laparoscopy has been used as a diagnostic test in CD and the presence of 
creeping fat is associated with transmural inflammation. However, mesenteric fat 
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wrapping has also been described in patients undergoing laparotomy for tuberculosis in 
India67, 68,69 . 
 
 
.  
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ASCA 
Anti-Saccharomyces cerevisiae antibodies (ASCA) are antibodies directed primarily 
against a 200 kDa- phosphopeptidomannan cell wall component of the common baker’s 
or brewers yeast’ Saccharomyces  cerevisiae70.  
ASCA positivity may demonstrate disturbed immune response to normal gut microbes. 
This was demonstrated from a study from Switzerland where lymphocytes from patients 
with CD, ulcerative colitis, and healthy controls were tested for their proliferative 
response after stimulation with the yeast antigen mannan. Only lymphocytes of ASCA-
positive patients with CD proliferated after stimulation with mannan. Thus a disturbed 
humoral and cellular response to the yeast antigen mannan was specifically seen in a 
subgroup of CD patients71.  The proposed mechanism of ASCA formation was leakiness 
of gut barrier but evidences are contradictory. In a study from Austria intestinal 
permeability was measured by lactulose/mannitol test and ASCA was quantified by using 
ELISA. Elevated serum levels of anti-S. cerevisiae antibodies did not  seem to result 
primarily from a defect of the gut barrier72. 
 
The prevalence of ASCA (Table 3) has varied from 30% to 70% in various studies with 
studies from west reporting a higher prevalence 73, 74,75. Evidence suggests that these 
antibodies may predict the development of IBD years before the disease occurs76. ASCA 
may also be seen in 1 to 7% of  normal healthy subjects 77, 78. Sensitivity of ASCA 
testing ranges from 41%-76%, PPV 88% and NPV 68%79. ASCA is also seen in first 
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degree relatives of patients with CD with a higher frequency than normal and may predict 
development of CD in future80,81. Also higher concordance of ASCA in monozygotic 
twins indicate genetic predisposition to develop ASCA antibody82. ASCA IgG and IgA 
levels in CD patients are highly variable83,  . 
 
Table 3: Prevalence studies of ASCA in CD 
 Number of 
patients 
Prevalence 
% 
Desplat-Jégo S73 (France) 109 37.9% 
Kaila B74 (Canada) 114  34.2% 
Hisabe T75 (Japan )  68 45.6% 
Peeters M78(Belgium) 407 59.7% 
Seibold F84 (Germany) 71 68% 
Makharia 85 (India) 59 50.8% 
 
 
ASCA:  CD vs. ITB 
Two studies have been done in India to evaluate whether ASCA can distinguish Crohn’s 
disease from intestinal tuberculosis85, 86 . Both studies failed to demonstrate usefulness of 
ASCA in this regards. First study was one in New Delhi where prevalence of ASCA IgG 
was 50.8% and 46.6% in patients with CD and ITB respectively. Second study was one in 
Lucknow where prevalence of ASCA was 62% and 50% in patients with CD and ITB 
respectively. Both the studies did not show a significant difference in ASCA prevalence 
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between ITB and CD group. Thus available evidence does not support a role of ASCA in 
distinguishing CD from ITB. 
 
ASCA: Phenotype and Progression 
Apart from playing a diagnostic role in CD, ASCA has been shown to correlate with 
disease phenotype as well as clinical course. Kim et al studied 115 patients with Crohn's 
disease, diagnosed and treated between 1990 and 2004 in Korea and found the anti-S. 
cerevisiae antibody prevalence in 38.3% patients87. There was no difference in anti-S. 
cerevisiae antibody expression between genders. The mean age at diagnosis was younger 
for the anti-S. cerevisiae antibody positive group than the negative group (25.3 years 
versus 29.7 years, p<0.05). Clinical manifestations and laboratory tests at diagnosis did 
not differ between the groups. The anti-S. cerevisiae antibody positive group had 
increased fibrostenosis (B2) and penetration (B3) compared to negative group. Anti-S. 
cerevisiae antibody positive patients were admitted to the hospital more frequently than 
anti-S. cerevisiae antibody negative patients (p<0.05). The Harvey-Bradshaw index score 
was higher in the anti-S. cerevisiae antibody positive group than in the negative group 
during the follow-up period (p<0.05). In addition, steroid (72.7% versus 52.1%, p<0.05) 
and immunosuppressive (45.5% versus 23.9%, p<0.05) treatments were more frequently 
given to the anti-S. cerevisiae antibody positive group.  
A study by Hungarian IBD Study Group  which included 558 patients with IBD found 
that ASCA positivity was  associated with ileal involvement, noninflammatory disease 
behavior and NOD2/CARD15 genotype, but not with risk for surgery88 .  Another study 
in 117 patients from CD from US showed that ASCA+ patients had a greater frequency 
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of mutant NOD2/CARD15 alleles and higher ASCA titers were associated with higher 
probabilities of ileal CD and stricturing/penetrating behavior independently of 
NOD2/CARD15 status. Higher ASCA titers were associated with more rapid 
development of complications89. A study among 139 children with CD in Canada showed 
that ASCA positivity predicted the early occurrence of complications but not surgery   in 
pediatric Crohn's disease patients. Another study from Italy showed that ASCA titers 
correlated significantly with disease activity, and children with severe active disease 
showed higher ASCA values compared to those in remission90. A study from UK in 231 
CD patients showed rapid disease progression among ASCA positive group91. Patients 
with Crohn's disease who are positive for ASCA IgA, IgG, or both, may define a subset 
of patients with Crohn's disease at increased risk for early surgery92. Table 4 summarises 
the phenotypic and prognostic correlates of ASCA positivity in various studies. 
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Table 4: ASCA positivity vs. phenotype and progression  
 Number of 
patients 
Comments  
Kim et al, 87 
 
115 Prevalence 38.3% 
Stenosis, fistula, hospitalisations, higher HBS score in 
ASCA positive group 
Hungarian 
IBD Study 
Group88  
558 Prevalence 59.3% 
Ileal disease & NOD2/CARD15 mutation more in 
ASCA positive group 
Dassopoulos 
T89  
117  Ileal disease & NOD2/CARD15 mutation  more in 
ASCA positive group 
Amre DK93  139 Pediatric population studied 
More early complication  
Smith BR91 231 Rapid progression of disease in ASCA positive group 
Forcione 
DG92  
70 More chance of early surgery in ASCA positive group 
Other Serological Markers of CD: 
Apart from ASCA, other serological markers have been studied in CD. One study from 
Czech Republic used carbohydrate assays based on oligosaccharide chitobioside 
carbohydrate - anti-chitobioside carbohydrate antibodies (ACCA), laminaribioside 
carbohydrate anti-laminaribioside carbohydrate antibodies (ALCA), and mannobioside 
carbohydrate - anti-mannobioside carbohydrate antibodies (AMCA). They   found that 
ASCA was still the best serological marker for Crohn's disease.94  Pancreatic 
autoantiboies were found to have a high PPV in distinguishing CD from ulcerative colitis 
in a study comprising of Chinese and Caucasian population95. Antibody to Escherichia 
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coli outer membrane porin (Anti OmpC) in CD has not been promising though it picks up 
a few cases missed by other tests70. 
 
ASCA in other diseases: 
Apart from CD, ASCA has been associated with other diseases like celiac disease and 
Behcet’s syndrome 96, 97, 98, 99, 100. A study from Holland showed ASCA in 18% of 
children and 61% of adult patients with celiac disease 97. Another study from Turkey 
suggested that patients with Behcet’s Syndrome  who have GI involvement may have 
higher levels of ASCA and this needs to be further studied98. Other conditions where 
ASCA may be positive include cystic fibrosis and ankylosing spondyloarthropathy 101, 
102. 
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Material and Methods 
 
 
Study design:   
Prospective descriptive pilot study. 
  
 
Sample size: 
 This was a pilot study where at least 20 subjects in each group were required. We 
studied 30 subjects in each group (ITB and CD).  
 
 
Subjects:  
Patients presenting to the outpatient or inpatient department of Christian Medical 
College, Vellore from January 2006 to October 2007 with confirmed diagnosis of 
Crohn’s disease or intestinal tuberculosis were included in the study after informed 
consent. Thirty patients were recruited in each group. 100 healthy controls were also 
studied to establish the normal value of ASCA in our population as no such data was 
available from our country.   
Diagnosis of Crohn’s disease and intestinal tuberculosis were based on standard clinical, 
radiological, endoscopic, histological criteria and response to treatment. 
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Diagnostic criteria of Crohn’s Disease:  
Presence of following features in varying combination 
Endoscopy: Skip areas, cobblestone appearance, linear or serpiginous ulcer, fistula  
Histopathology: Crypt architecture abnormalities, mononuclear infiltration, granulomas, 
transmural inflammation, segmental distribution of the lesion, patchy and focal 
inflammation. 
Radiology: Skip lesions, fistula, cobblestone appearance, deep linear ulcer, asymmetric 
involvement, creeping fat. 
Response to treatment  
 
Diagnostic criteria of Intestinal Tuberculosis:  
Presence of any of the following features in the appropriate clinical,  endoscopic or 
radiological profile suggestive of intestinal tuberculosis 
1. Histopathology 
a. AFB positive on histopathology or culture 
b. Caseating granuloma 
c. Large or confluent granuloma 
2. Response to treatment 
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Clinical profile, imaging studies, enoscopy and histopathology were evaluated in both 
groups of patients (CD and ITB) to assess the ability of the above to differentiate Crohn’s 
disease from Intestinal Tuberculosis 
 
 
Anti Saccharomyces cerevisiae Antibodies (ASCA) test 
After obtaining informed consent, 5 ml of venous blood was collected. The blood 
samples were stored at –20ºC.  Evaluation of Anti-Sachromyces cerevisiae mannan 
antibodies (ASCA) was done at Wellcome Microbiology laboratory, C.M.C., Vellore, 
using the IgG ASCA ELISA kits (AIDA diagnostics, Germany). Each kit has 96 wells 
and a maximum of 90 samples could be processed (remaining 6 needed for controls and 
calibrators).   
 
 
Principle of the test: 
ASCA –Ig G test is a solid phase enzyme immunoassay (ELISA) employing highly 
purified mannan for the detection of Ig G anti-Saccharomyces cervisiae antibodies in 
human serum. ASCA recognises specific mannan, a component of the outer wall of yeast. 
Serum samples diluted to 1:101 are incubated in the microplates coated with specific 
antigen. Patient’s antibodies, if present in the specimen, bind to the antigen. The unbound 
fraction is washed off in subsequent steps. Afterwards, anti-human immunoglobulins 
conjugated to horseradish peroxidase (conjugate) are incubated and react with the 
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antigen-antibody complex of the samples in the microplates. Unbound conjugate is 
washed off.  
Addition of 3,5,3',5'-tetramethylbenzidine (TMB)-substrate generates an enzymatic 
colorimetric (blue) reaction, which is stopped by diluted acid (stop solution) and colour 
changes to yellow. The rate of colour formation from the chromogen is a function of the 
amount of conjugate bound to the antigen-antibody complex and this is proportional to 
the initial concentration of the respective antibodies in the patient sample. 
 
 
Assay procedure: 
Prior to pipetting, concentrated reagents were diluted. Concentrated sample buffer was 
diluted to 1:5 with distilled water. Concentrated wash buffer was diluted to 1:50 with 
distilled water and 200ml of diluted wash buffer was prepared. Serum samples were 
diluted to 1:101 with sample buffer and they were mixed well. 300 micro litre of diluted 
wash buffer was pipetted into each of the 96 wells and left for 20 seconds after which 
after it was cleared. This process was repeated twice. 
 
100 micro litre of each patient’s diluted serum was pipetted into designated microwells. 
100 micro litres of calibrators, negative and positive controls were pipetted into the 
designated wells. The microwells were incubated at room temperature for 30 minutes. 
The microwells were then washed thrice with diluted washing buffer.  Next, 100 micro 
litre of conjugate was pippeted into each well which was incubated at room temperature 
for 15 minutes. Again, the microwells were washed thrice with diluted washing buffer. 
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100 micro litre of TMB substrate was pipetted into each well which was incubated at 
room temperature for 15 minutes in dark. Finally 100 microlitre of stop solution was 
pipetted into each well and was incubated at room temperature for 5 minutes. The 
absorbance was read at 450 nm within 30 minutes. 
 
The optical density (OD) of each calibrator (y axis) was plotted against the corresponding 
concentration values in U/ml (x axis). From this plot the antibody concentration of each 
patient and control sample was calculated by finding out the concentarion corresponding 
to their respective OD values.  
 
 
 
Statistical Methods 
Average value was denoted as mean with standard deviation for normally distributed 
continuous variables and as median with interquartile range for non-normally distributed 
continuous variables. The results between ITB and CD groups were compared for 
statistically significant difference. For categorical variables (including ASCA result) chi 
square test was used. For continuous variable with normal distribution, t test was used. 
For continuous variable with non-normal distribution, Mann-Whitney’s U test was used. 
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p value of <0.5 was considered significant. The statistical analysis was done using SPSS 
software for windows version 11. 
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Results  
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Demographic features in patients with CD and ITB are shown in Table 1. There was no 
significant difference in age, sex and geographical location in patients with CD and ITB. 
Figure 1 shows the sex and state wise distribution of patients. In ITB group, 18 patients 
were from east India, 10 from south India and 2 from central India. In CD group 20 
patients were from east India, 9 from south India and 1 from central India.  
 
 
 
Table 1: Demographic features 
 CD (n=30) ITB (n=30) p 
Age (yrs.) 33.9 + 15.2 35.1 + 12.2 0.72 
Sex (M/F) 21/9 16/14 0.29 
Geographic distribution 
(East/South/Central) 
20/9/1 18/10/2 0.78 
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Figure 1: Geographic distribution of patients with CD and ITB 
 
 
Clinical Profile: 
Symptoms: 
The median duration of symptoms in patients with ITB was 3 months (range 1 month to 2 
years) while it was 2 years (range 2 months to 15 years) in patients with CD,  the 
difference being statistically significant (p <0.001,  Mann Whitney test).  
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Clinical presentations of patients with ITB and CD are shown in Table 2.  Dull aching 
and poorly localised abdominal pain was the commonest symptom in patients with CD 
(60%) and ITB (70%). Diarrhoea and fever were similar in both groups. Blood mixed 
with stool was seen more often in patients with CD (p=0.006).  Anorexia (P=0.008) and 
weight loss (P=0.067) were seen more often in ITB. Clinical Examination of abdomen 
showed right iliac fossa mass in two patients with CD. In patients with ITB right iliac 
fossa mass was revealed in two patients, hepatosplenomegaly in one, hepatomegaly in 
one and cervical lymphadenopathy in two patients.   
 
 
 
Table 2: Clinical features 
 CD ( n=30) ITB ( n=30) p 
Abdominal pain 18(60%) 21(70%) 0.59 
Diarrhea  14(46.7%) 12(40%) 0.8 
Weight loss 13(43.3%) 21(70%) 0.067 
Anorexia  12(40%)  23(76.7%) 0.008 
Blood in stool 11(33.3%) 1(3.3%) 0.006 
Fever  8(26.7%) 9(30%) 1.0 
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Complications:  
Intestinal and extraintestinal complications in patients with CD and ITB are shown in 
Table 3 
 
Crohn’s disease: Two patients had internal fistula (jejunocolic and colovesical), 4 had 
fistula in ano and two had anal fissure. Extraintestinal manifestations were present in 4 
patients – 3 had arthralgia, 1 had pyoderma gangrenosum and 3 had oral ulcers alone. 
Thirteen patients underwent surgery for their disease – 5 had small bowel surgery for 
strictures, 7 had right hemicolectomy for ileocolonic disease and 1 had fistulectomy for 
perianal fistula.  
 
Intestinal Tuberculosis: Two patients had internal fistula ( duodenocolic and 
jejunocolic) and 1 had fistula in ano. Extraintestinal manifestation was present in only 1 
patient who had arthralgia. Three patients underwent surgery for their disease – 1 had 
small bowel surgery for strictures and other two had partial colonic resections as 
treatment of internal fistulas. Results show that occurrence of fistula and extraintestinal 
manifestations were not significantly different between the two groups.  Patients with CD 
underwent surgery significantly more often compared to ITB patients. 
Table 3: Complications  
 CD (  n=30) ITB ( n=30) p 
Fistula 6 (20%) 3(10%) 0.47 
Extraintestinal 
manifestations 
4 (13.3%) 1(3.3%) 0.35 
Surgery  14(46.6%) 3(10%) 0.007 
 46
Investigations: 
 
Blood tests: 
Table 4 shows comparison of laboratory tests between patients with CD and ITB. Lab 
investigations revealed low albumin (<3.5 g/dl in 38 patients), high ESR (>30 in 40 
patients) and borderline low haemoglobin (<11.0g% in 32 patients) in most patients. ESR 
was significantly higher in ITB group compared to CD (p=0.05).  
 
 
Table 4: Laboratory tests  
Test CD ITB p 
CRP(%Positive) 71.4  (n=28) 75   (n=12) 1.0 
Hb(g%) 11.0 (n=30) 10.5 (n=30) 0.33 
ESR(mm/hr.) 44.1 (n=30) 62.8 (n=25) 0.05 
Albumin (g/dl) 3.3   (n=30) 3.0    (n=29) 0.19 
 
 
Endoscopy:  
Colonoscopic finding in patients with CD and ITB are shown in Table 5. Colonoscopy 
was performed  for all patients with CD and  24 patients with ITB.  Twenty five (83%)  
patients with CD had colonic involvement. Mucosal erythema, loss of vascular pattern, 
ulcerations and friability were common abnormalities seen. Eleven patients had aphthous 
 47
ulcers and skip lesions , nine  patients had pseuopolyps and  3 had  cobblestone pattern . 
Eight patients had colonic strictures (5 in transverse colon, 2 in sigmoid colon and 1 in 
rectum) and ileum could not be visualized in these patients.  
 
Twenty three patients with ITB(95.8%) had colonic involvement. Contiguous 
involvement of mucosa, ulceronodular lesions, ulcerations and friability were common 
abnormalities detected.  Pseudopolyps were seen in two patients and two had skip 
lesions. Terminal ileum could not be visualized in 9 patients - four patients had colonic 
strictures ( 2 in ascending colon and  2 in transverse colon) while in five patients the IC 
valve was narrowed and deformed.  
 
Table 5 : Colonoscopic findings in patients with TB and CD 
Findings  CD (n=30) ITB(n=24) p 
Aphthous ulcer 11(36.3%) 4(16.7%) 0.13 
Skip lesions 11(36.3%) 2(8.3%) 0.02 
Cobblestone 
pattern 
3(10%) 0(0%) 0.25 
Pseudopolyp  9(30%) 2(8.3%) 0.09 
Stricture  8(26.6%) 4(16.7%) 0.51 
Narrowed IC valve 3(10%) 5(20.8%) 0.44 
Patulous IC valve 2(6.6%) 2(8.3%) 1.00 
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Apart from the presence of skip lesions (p=0.02), other colonoscopic findings were not 
helpful in differentiating CD from ITB. 
 
Five patients with CD had UGI involvement on enoscopy and histology (4 in stomach 
and 1 in duodenum) . 
 
One patient had intraoperative enteroscopy which revealed multiple ileal strictures. 
 
 
 
Radiology:  
Radiological tests included ultrasonogram of abdomen, CT  abdomen and barium meal 
follow through(BAMFT). These tests were individualized according to patient’s 
indications and physician preference.   
 
Crohn’s disease:  Twelve patients had BAMFT and seven had CT abdomen. Eleven 
patients had abnormalities on BAMFT – 7 patients had both large and small bowel 
abnormalities whereas 4 patients had only small bowel abnormalities. Abnormalities 
included stricturing, ulceration, mucosal nodularity/edema  and loss of mucosal folds. All 
seven patients who had CT abdomen showed abnormal finings which included bowel 
wall thickening, deformity, luminal narrowing and mesenteric adenopathy. 
Ultrasonogram of abdomen was abnormal in 2 patients and both had right colonic wall 
thickening.  
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Intestinal tuberculosis: Seven patients had BAMFT and six patients had CT abdomen. 
Six patients had abnormalities on BAMFT – 5 patients had both large and small bowel 
abnormalities whereas 1 patient had only small bowel abnormalities. Abnormalities 
included stricturing, deformity, mucosal nodularity and ulcerations. All six patients who 
had CT abdomen showed abnormal findings which included bowel wall thickening, 
luminal narrowing, deformity and mesenteric adenopathy (similar to patients with CD). 
Ultrasonogram of abdomen was abnormal in 5 patients - 4 had ileocecal region bowel 
wall thickening while one had ileal thickening. 
Table 6 compares radiological findings in patients with CD and ITB who had BAMFT 
and/or CT abdomen. Contracted cecum, narrowed IC valve and mesenteric adenopathy 
was significantly commoner in patients with ITB. 
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Table 6: Comparison of radiological finings of CD and ITB patients 
Findings  CD(n=19) ITB(n=13) p 
Contracted cecum 1(5.3%) 8(61.5%) <0.001 
Narrow IC vave 1(5.3%) 5(38.5%) 0.03 
Patulous IC valve 1(5.3%) 0(0%) 1.0 
Colonic stricture 0(0%) 2(15.4%) 0.16 
Ileal stricture 5(26.3%) 1(7.7%) 0.36 
Multiple ileal strictures 4(21.1%) 0(0%) 0.13 
Aphthous ulcer 2(10.6%) 1(7.7%) 1.0 
Pseudopolyp  0(0%) 0(0%) 1.0 
Cobblestone pattern 1 1 1.0 
Mesenteric LN 2 7 0.02 
Fistula 2 2 1.0 
 
 
 
Histopathology:  
 
Histological features suggestive of CD were seen 90% of CD patients and these included 
crypt architecture abnormalities, mononuclear infiltration, granulomas, transmural 
inflammation, segmental distribution of the lesion and patchy and focal inflammation. 
Remaining three patients had non-specific histological features and in them, clinical and 
radiological features along with response to therapy formed the basis of diagnosis. 
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Histological features suggestive of ITB was seen in 70% of ITB patients and these 
included caseating granuloma, large or confluent granuloma and presence of AFB in 
tissue section (or culture of tissue). In the remaining patients clinical and radiological 
features along with response to therapy formed the basis of diagnosis as was the case 
with 3 patients with CD. Table 7 shows the comparison of histological findings between 
the two groups. 
 
Table 7: Comparison of histological findings between the two groups 
Findings  CD (n=30) ITB ( n=24) p 
Confluent granuloma 0(0%) 9(37.5%) <0.001 
Discrete granuloma 9(30%) 11(45.8%) 0.27 
Microgranuloma  3(10%) 0(0%) 0.25 
Caseous necrosis 0(0%) 2(8.33%) 0.19 
AFB positive 0(0%) 9(37.5%) Not relevant 
 
 
Site of disease 
The site of intestinal involvement is shown in figure 2. Ileocolonic disease was 
commonest followed by colonic disease. 
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Disease Location
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Figure 2: Disease Location 
 
 
 
While endoscopy was able to detect colonic and terminal ileal lesions, radiology was 
especially helpful in patients with small bowel disease and colonic strictures (where 
entire colon and terminal ileum could not be visualised). Table 8 shows the site of disease  
picked up on radiological and endoscopic investigations. Colonic lesions were frequently 
missed by radiological investigations. 
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Anti Saccharomyces cervisiae Antibody test – Results  
 
ASCA ELISA test was done on 100 controls to establish the normal “cut-off” antibody 
levels in the population. The mean optical density value plus 2 standard deviation in 
controls was  6.9 U/ml and was taken as “cut off” value. Patients with value above 
6.9U/ml were considered to have ASCA test positive. 
Figure3 and Table 8 shows ASCA results of CD patient compared with ITB. 
 
Figure 3 
Table 8: ASCA results of CD patient compared with ITB 
   ASCA CD ITB p (Chi square) 
Positive  9(30%) 3(10%) 
Negative  21(70%) 27(90%) 
Total 30 30 
0.10 
30% of patients with CD had ASCA positive as compared to 10% of patients with ITB.  
ASCA results
27
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3
9
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ITB
CD 
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Table 9 compares demographic, clinical, investigation profile between ASCA positive 
and negative groups  in CD. No significanr difference was observed in any parameter 
tested.  The occurrence of stricturing and fistulising disease, small bowel disease, need 
for surgery, marker of disease activity (CRP, ESR, Harvey Bradshaw Score>4) and 
clinical course was similar in the two groups. 
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Table 9: Comparison of ASCA positive and negative patients with CD  
 
 ASCA positive (n=9) ASCA negative (n=21) p 
Sex (females, %) 44.4 28.6 0.43 
Age (yrs.) 27(25) 35(20.5) 0.46 
Region(South/East/Others) 22.2/66.7/11.1 33.3/66.7/0 0.26 
Duration of illness (yrs.) 1.5(4.1) 2(4.7) 0.86 
Abdominal pain (%) 77.8 52.4 0.25 
Diarrhoea (%) 55.6 42.9 0.69 
Blood in stool (%) 22.2 38.1 0.68 
Anorexia (%) 33.3 42.9 0.70 
Weight loss (%) 33.3 47.6 0.69 
Fever (%) 33.3 23.8 0.67 
Fistula (%) 22.2 19 1.0 
Bowel Stricture (%) 44.4 57.1 0.69 
Extra intestinal features 22.2 9.5 0.56 
Ileal disease (%) 88.9 81 1.0 
Hb (g %) 11.4(.5) 11.3(3.8) 0.63 
ESR (mm/hr.) 65(52) 33(23.5) 0.07 
CRP positive 77.8 61.9 0.4 
Albumin (g %) 3.4(0.9) 3.3(1.4) 0.89 
HBS > 4 11.1 4.8 0.52 
Non specific biopsy (%) 11.1 9.5 1.0 
Surgery (%) 33.3 47.6 0.69 
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Discussion 
 
The study was aimed at assessing ASCA as a serological marker to distinguish between 
CD and ITB. Clinical and investigation profile of the two groups were also compared to 
assess theirability to ifferentiate CD from ITB. Being a pilot study only 30 patients with 
CD and 30 with ITB were studied. 
The mean age distribution between the two groups was comparable. Males predominated 
in the CD group while  the ITB group had almost equal representation of both males and 
females. Most patients studied came from East and South India reflecting the patient 
population visiting CMC.  Geographic distribution of patients was similar in CD and ITB 
groups.   
 
As reported in literature abdominal pain was the commonest symptom in both groups24.  
Anorexia was significantl more common in ITB group while  blood mixed stool was 
significantly more common in CD group. Apart from these, other symptoms were 
comparable between the two groups. Thus, blood mixed stool was a good indicator of 
CD. Extraintestinal manifestations were uncommon in both groups.  Fistulising disease 
and extraintestinal manifestations were more often seen in CD, but the ifference was not 
statistically significant. 
 
 57
Anemia, and hypoalbuminemia were the non specific laboratory abnormalities seen in 
both groups. While CRP positivity did not differ between the two groups, ESR was 
significantly higher in the ITB groups.  
 
Colonoscopy showed skip lesions were significantly more common in CD. Aphthous 
ulcers and cobblestone pattern were more common in CD as compared to ITB but the 
difference was not statistically significant. Patulous IC valve and pseudopolyps are 
reported to be commoner in ITB compared with to CD. However this was not reflected in 
the present study. 
 
 
Radiological studies (Barium Meal Follow Through,  CT Abdomen) showed that 
contracted cecum, narrow IC valve and mesenteric adenopathy were significantly more 
common in ITB patients. Other findings were similar in both groups. This observation is 
similar to that reported in literature where  findings like   strictures and  fistulas, fold 
thickening and  mucosal nodules have been described in both conditions43, 61.  
 
Histopathological findings in C D and ITB were similar except for confluent granuloma 
being more common in ITB (p <0.001).  
 
As we wanted to test the ability of ASCA to differentiated CD and ITB, confirmed cases 
of CD and ITB were recruited in the study.  Patients with ambiguous histology and no 
response to therapy were not included.  
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ASCA positivity  has varied from 30 to 70% in various series73, 74, 75.  In our study 30% 
of patients with CD were ASCA positive which is on the lower end of spectrum of 
reported prevalence.  10% of patients with ITB were ASCA positive but the difference 
failed to reach statistical significance. Two other studies done in India also showed 
similar results  of ASCA positivity in CD and ITB(Table 10).  The two studies from India 
showed higher  prevalence rates and less pronounced difference of ASCA in CD and ITB  
as compared to the current study (Table 10). The reason could be because we established 
our own ‘ASCA cut off ’ level by analysing serum of 100 healthy controls . 
 
Table 10: ASCA in differentiating CD from ITB (NS- not significant) 
 ASCA in CD ASCA in ITB p 
Makharia et al85 50.8% 46.6% NS 
Ghoshal et al86 62% 50% NS 
Current study 30% 10% NS 
 
 
 
ASCA has also been correlated with phenotype and course of CD with younger age of 
onset, ileal disease, stricturing and fistulising disease being more common in patients 
with a positive serology along with a higher chance of undergoing surgery 87, 88, 89, 91, 92. 
Similar findings were not seen in our study. An interesting finding in our study was that 
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eight of the nine patients with CD with ASCA positive had ileal involvement. Hence 
ASCA positivity may point to small bowel involvement in CD. 
 
Thus ASCA has a low prevalence among CD patients in our country and is unable to 
differentiate CD from ITB.   
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Conclusions 
Differentiating CD from ITB continues to be a challenging problem.  Our study confirms 
the results of 2 other studies from India that ASCA does not help to differentiate CD from 
ITB 85, 86.  Presently, a combination of clinical features, endoscopy, histology, radiology 
and response to treatment continues to be the mantra to  differentiate these two 
conditions. We need to continue to strive to develop new tests to help clinicians 
differentiate the two conditions. 
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APPENDIX I - PROFORMA 
 
Case Number 
Name 
Age 
Sex 
Hospital Number 
Address 
 
Date of diagnosis 
Final diagnosis and basis of diagnosis 
 
Site  of involvement  
Harvey Bradshaw score for Crohn’s Disease 
 
 
ASCA IG G 
 
 
CLINICAL DETAILS 
Abdominal pain  
Duration 
Location  
Intensity 
Character 
 
Diarrhoea  
Frequency 
Volume  
 74
Blood/mucus 
 
Constitutional symptoms  
Anorexia 
Weight loss 
Fever 
Others 
 
 
 
 
Anal canal lesions  
Fissures 
Ulcers 
Stenosis 
 
 
Extraintestinal manifestations  
Musculoskeletal Manifestations 
Mucocutaneous Manifestations 
Ocular Manifestations 
Hepatobiliary Manifestations 
Renal and Genitourinary Manifestations 
Coagulation and Vascular Complications 
Other Manifestations 
 
 
Complications ( intestinal/extraintestinal) 
 
 
Surgeries  
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Past history 
 
 
Personal history 
 
 
Family histoy 
 
 
Treatment history 
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Physical examination 
Height:  Weight:  BMI: 
Pulse rate 
Blood pressure 
Pallor 
Icterus 
Clubbing 
Lymphadenopathy     
Oral hygiene 
Skin 
Perianal area  
 
Systemic examination 
 Abdominal  
 Musculoskeletal 
 Respiratory  
 Others  
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Investigations 
1. CBC profile, ESR, CRP 
2. Serum biochemistry  
3. Radiologic findings 
       CXR, U/S Abdomen, CT Abdomen 
 
 
 
4. Endoscopy  &  Colonoscopy 
5. Histologic examination 
6. Others  
